Merck and Moderna Advance Personalized Cancer Vaccine Through Phase 3

Personalized cancer vaccine for high-risk skin cancer recurrence shows promise in phase 3 trials

Merck and Moderna are advancing a personalized cancer vaccine through phase 3 trials for high-risk skin cancer recurrence. This development could improve survival for patients with limited treatment options by reducing cancer recurrence.

The source is unreachable; details remain with the original report.

Source: Fierce Biotech